HDV
Conditions
Keywords
HBV, HDV, cirrhosis, Thailand
Brief summary
There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment
Detailed description
The prevalence of HDV remains ill-defined, mainly for lack of appropriate testing and screening. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. This data will inform the guideline whether HDV screening among HBV/HIV is required. This study has plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. This Nationwide survey of HDV is collaboration between Thai liver society, Thai AIDS society, Thai Red Cross AIDS research centre, Faculty of Medicine Chulalongkorn University, and AIDS TB and STI Control Division, Department of Disease control, MOPH Thailand. All findings will be shared and discussed to develop the National guideline for screening, treatment and care.
Interventions
None listed
Sponsors
The HIV Netherlands Australia Thailand Research Collaboration
King Chulalongkorn Memorial Hospital
Thai Red Cross AIDS Research Centre
Siriraj Hospital
Taksin Hospital
Gilead Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, aged 18 years and older 2. Chronically-infected with HBV, as defined by: Positive Hepatitis B surface antigen HBsAg) or HBV DNA result with a subsequent positive HBsAg or HBV DNA result at least 6 months after first positive result 3. Provide signed and dated informed consent form.
Exclusion criteria
Non chronic HBV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prevalence of HDV | 1 year | prevalence of HDV in patients with cirrhosis |
| proportion of participants with detectable HDV RNA among seropositive anti HDV | 1 year | proportion of participants with detectable HDV RNA among seropositive anti HDV with cirrhosis |
| predictive risk of HDV infection | 1 year | predictive risk of HDV infection |
| HDV subtype | 1 year | HDV subtype among people with cirrhosis |
| performance of antiHDV commercial kits | 1 year | performance of antiHDV commercial kits |
| prevalence of HDV among HBV/HIV before combination antiretroviral therapy | 1 year | prevalence of HDV among HBV/HIV before combination antiretroviral therapy |
| prevalence of HDV among HBV/HIV after combination antiretroviral therapy | 1 year | prevalence of HDV among HBV/HIV after combination antiretroviral therapy |
Countries
Thailand
Contacts
PRINCIPAL_INVESTIGATORAnchalee Avihingsanon, MD, PhD
Thai Red Cross AIDS Research Centre
PRINCIPAL_INVESTIGATORPisit Tangkijvanich, MD
Biochemistry, Faculty of Medicine, Chulalongkorn University
Outcome results
None listed